Home > Products > CD44 & CR3 > Recombinant Human Anti-CD44 x Human Anti-CR3 Bispecific Antibody (scDiabody-CH3)

Recombinant Human Anti-CD44 x Human Anti-CR3 Bispecific Antibody (scDiabody-CH3)  (SCDBC-H295)

Recombinant Anti-CD44 x Anti-CR3 Bispecific Antibody (scDiabody-CH3) is a fusion protein of two scDiabodies connected together by a CH3 region. In single-chain Diabodies, an additional connecting linker is introduced between chains of the anti-CD44/anti-CR3 diabody. The scDiabody with two specificities is fused to each of the CH3 chains to extend half-life. This BsAb can recruit macrophages to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.

Specifications

Targets
CD44 & CR3
Type
Constant Domain-extended Bispecific Fragments
Species Reactivity
Human
Target 1
CD44
Host Animal 1
Human
Target 2
CR3
Host Animal 2
Human
Application
FuncS; Promising therapeutic agent
Related Disease
Glioblastoma; Squamous cancer

Targets

Target 1
CD44
Gene ID
UniProt ID
Alternative Names
CD44; CD44 antigen; ECMRIII; Extracellular matrix receptor III; HCAM; Homing cell adhesion molecule; Pgp-1; phagocytic glycoprotein-1; HUTCH-1; Ly-24; Pgp-1; HERMES; AU023126; AW121933; AW146109
Target 2
CR3
Gene ID
UniProt ID
Alternative Names
C3AR1; complement C3a receptor 1; AZ3B; C3AR; HNFAG09; CR3; Complement receptor type 3; CD11b/CD18; Mac-1; Macrophage antigen 1; αmβ2

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD44 x Human Anti-CR3 Bispecific Antibody (scDiabody-CH3) (SCDBC-H295). Click the button below to contact us or submit your feedback about this product.

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY
Related products of "CD44 & CR3"
See other bsAb targets related to "CD44"

Online Inquiry

24x7 Service quality
USA

Tel:
Fax:
Email:

UK

Tel:
Email:

Germany

Tel:
Email: